Onglyza Lawsuit

Onglyza Overview

Patients who have suffered from heart failure and other cardiovascular adverse effects while taking Onglyza may be eligible to pursue a claim and seek financial compensation.

Onglyza is an antidiabetic drug that increases insulin production in the body after meals, while reducing glucagon and preventing the liver from releasing excess glucose. Studies have found that the medication increases the risk of heart failure. Pending lawsuits against Onglyza’s manufacturer Bristol-Myers Squibb and AstraZeneca were recently consolidated in a Kentucky federal court.

If you or a loved one were treated with Onglyza and suffered from heart failure or other cardiac issues, contact Maxwell Law Group LLP today. We can answer your questions and review your case for free.

For help understanding your options if you’ve been injured by Onglyza, reach out to our firm or call (844) 525-7155.

What is Onglyza?

Onglyza (generic name: saxagliptin) is an oral type 2 diabetes medication which helps lower blood glucose. It belongs to a drug class called DPP-4 inhibitors like Januvia. It gained popularity among consumers because it does not cause weight gain, unlike other antidiabetic medications.

The FDA approved Onglyza in 2009. In 2010, FDA approved a combination drug called Kombiglyze XR, a combination of saxagliptin and metformin in an extended-release pill form. Both these drugs are designed to control blood sugar levels in patients who are not experiencing diabetic ketoacidosis.

Sales from Onglyza were estimated at $786 million in 2015 and analysts say that by 2018, annual sales of the drug could skyrocket to $2.47 billion.

Onglyza Quick Facts



Medication for type 2 diabetes



Heart failure and cardiovascular problems




Bristol-Myers Squibb and AstraZeneca-Pharmaceuticals

How Does Onglyza Work?

Insulin is a hormone that allows the body to use glucose by helping cells absorb sugar from the bloodstream. Type 2 diabetic patients have lowered insulin production and develop resistance to the hormone, resulting in increased blood glucose levels.

Onglyza is a dipeptidyl peptidase-4 (DPP-4) inhibitor, which increases a natural hormone called incretin, thereby boosting insulin production in the body. The inhibition of DPP-4 also decreases glucagon production in the pancreas, which contributes to lower blood glucose levels.

onglyza lawsuit overview

Risks and Warnings

In 2013, the FDA released a safety communication indicating that Onglyza may lead to increased risk of pancreatitis and pre-cancerous cells in the pancreas.

In 2014, the FDA warned that Onglyza may cause disabling and severe joint pain.

In 2016, FDA released a safety communication report adding new warning labels to Onglyza and other saxagliptin medications. After two clinical trials, it was shown that these antidiabetic drugs can increase the risk of heart failure, especially in patients who have already been diagnosed with heart and kidney disease.

Heart failure or congestive heart failure occurs when the heart does not pump a sufficient amount of blood to meet the body’s needs. Symptoms of heart failure include the following:

  • Shortness of breath
  • Weakness
  • Increased or irregular heartbeat
  • Swelling in the legs, knees, and ankles
  • Persistent cough
  • Blood-tinged phlegm

In addition to heart failure, other FDA warnings and potential side effects from Onglyza include pancreatitis, pancreatic cancer, and severe and debilitating joint pains.

The time you have to pursue a claim is limited. Do not wait to reach out to our firm or call (844) 525-7155 to see if you have a case.

Injuries from Onglyza

The FDA’s warning about Onglyza stemmed from a clinical trial called Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus (SAVOR) conducted in 2013.

The study followed 16,492 patients with type 2 diabetes and who were diagnosed or were at risk of cardiovascular events. It was concluded that hospitalization due to heart failure was increased with saxagliptin (Onglyza) use.

Patients taking Onglyza had hospitalization rates of 3.5% due to heart failure, versus 2.8% in the placebo group—a 27% increased risk for patients treated with the drug.

Onglyza Lawsuits

There are currently more than 200 pending lawsuits against the Bristol-Myers Squibb Company, and AstraZeneca-Pharmaceuticals. These lawsuits were filed by patients and families affected by Onglyza’s serious adverse effects, specifically heart failure and its complications.

The lawsuits claim that these pharmaceutical companies failed to warn consumers about the dangers of the drug. They continued to profit from the medication for years before a credible study observing its risks and adverse effects was completed, all the while marketing Onglyza and Kombiglyze XR  as a safe antidiabetic drug.

In February 2018, 80 Onglyza lawsuits were consolidated into a multidistrict litigation (MDL) in the US District Court Eastern District of Kentucky. Bellwether trials are expected to be scheduled soon.

onglyza litigation timeline

How Maxwell Law Group Can Help

If you or your loved one suffered from heart failure or other cardiovascular events from taking Onglyza, Maxwell Law Group can help get you the compensation you deserve. Call (844) 525-7155 or fill out the form below and we’ll investigate your case at no charge to you.

You Deserve to be Compensated

6 + 15 =

We're On Your Side

Our attorneys are always ready to speak with you about your personal situation. Every day we help people in situations similar to yours. Our team can guide you each step of the way and make sure you get the financial compensation you deserve.

While our physical offices are in Utah and Washington DC, we offer our services nationwide. We'd be honored to discuss your case with you free of charge.

Please note that the law limits the time you have to pursue a claim or file a lawsuit for an injury. If you think you have a case, don't wait to take action. Contact us today.

To speak with us directly, call (844) 525-7155. We want to hear about your situation and help you through this difficult time.

Maxwell Law Group LLP

Maxwell Law Group LLP
© 2021 All Rights Reserved

Washington DC Office

By appointment only
1101 Connecticut Avenue NW
Suite 450
Washington, D.C. 20036

Utah Office

520 N Marketplace Drive
Suite 200A
Centerville, UT 84014

ATTORNEY ADVERTISING. Nothing on this site should be taken as legal advice for any individual case or situation. This website is not intended to create, and receipt of viewing does not constitute, an attorney-client relationship. Sensitive information should not be submitted through this website as it may be considered confidential or privileged. References to prior results do not guarantee a similar outcome. The firm has attorneys licensed to practice law in Utah and Washington D.C., but the attorneys may also be admitted on an individual basis in additional state and federal courts across the United States. The location of the firm's offices are listed on this website. The firm associates with co-counsel law firms to jointly represent clients in some matters. Gregory Maxwell is the attorney responsible for the contents of this website.

Share via
Send this to a friend